Those Viral Bodega Peptides Aren’t Actually Peptides

The peptides you might buy from a bodega or online for wellness purposes could be entirely inert or contain unknown harmful substances.

Testing of peptides purchased from a viral New York City bodega revealed that the products did not contain the active ingredients listed on their labels. WIRED purchased four varieties—PT-141, BPC-157, NAD+, and retatrutide—for a total of $376.20 from the shop Mr. Green. These substances, popular for purported benefits in weight loss, healing, and libido, were sold in unlabeled packaging and advertised for "research use only." Independent testing conducted by Finnrick, a startup that facilitates peptide analysis, found that the samples contained low levels of heavy metals and endotoxins, suggesting they were not actively harmful. However, none of the tested vials contained their advertised active ingredients. Experts suggest that improper storage could degrade sensitive peptide compounds, or that the vials were intentionally mislabeled. This finding aligns with an observed uptick in similar "dud" results from peptide testing companies, potentially linked to the rise of "turnkey" services that enable new businesses to easily enter the peptide market, often sourcing from the same suppliers. Other vendors have also reported similar issues with unidentifiable substances, highlighting a broader concern about the lack of quality control and accurate labeling in the rapidly growing, largely unregulated peptide industry.

The widespread availability of mislabeled or inert peptides indicates a significant gap in oversight for a booming market. "Turnkey" services are lowering the barrier to entry, leading to a proliferation of brands that may share unreliable suppliers. This dynamic suggests a market driven by hype and accessibility rather than scientific validation or regulatory compliance, where consumers are largely unprotected from substandard or fraudulent products.

This situation signals a critical need for consumer protection and regulatory clarity in the burgeoning peptide industry, which is estimated to be worth billions. The FDA has warned against such practices, but enforcement actions appear limited, particularly against brick-and-mortar sellers. As more legitimate health platforms prepare to enter the peptide market, the current ecosystem of questionable vendors creates a confusing and potentially dangerous environment for consumers seeking these compounds.